Showing results (121-130 of 299) with videos related to
Sort By:
Pageof 30
JTO Clinical and Research Reports|March 7, 2023
Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter StudyJingran Ji, Jacqueline V Aredo, Andrew Piper-Vallillo, et al.Molecular Diagnosis & Therapy|March 31, 2017
Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung CancerHelio A Costa, Joel W Neal, Carlos D Bustamante, et al.Journal of Cutaneous Pathology|January 15, 2016
Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapyKurt B Schaberg, Roberto A Novoa, Heather A Wakelee, et al.American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 30, 2025
Liquid Biopsy Approaches for Cancer Characterization, Residual Disease Detection, and Therapy MonitoringJacqueline V Aredo, Amna Jamali, Jessica Zhu, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 24, 2017
Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancerMichael F Gensheimer, Julian C Hong, Christine Chang-Halpenny, et al.Lab on a Chip|August 24, 2013
Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochipsChristopher M Earhart, Casey E Hughes, Richard S Gaster, et al.Cancer Reports (Hoboken, N.J.)|August 28, 2025
Etirinotecan Pegol (NKTR-102) in Patients With Active Brain Metastases From Lung or Breast CancerSeema Nagpal, Kim-Son Nguyen, Sophie Bertrand, et al.Medrxiv : the Preprint Server for Health Sciences|March 31, 2025
Napsin A-specific T cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancerNatalie J Miller, Christina S Baik, Joel W Neal, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 18, 2012
A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501Heather A Wakelee, Ju-Whei Lee, Nasser H Hanna, et al.Cancer Treatment Reviews|August 29, 2022
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature reviewJeffrey Graham, Arndt Vogel, Ann-Lii Cheng, et al.Pageof 30